Ryu Watanabe1, Marc Hilhorst1,2, Hui Zhang1, Markus Zeisbrich1, Gerald J Berry3, Barbara B Wallis1, David G Harrison4, John C Giacomini5, Jörg J Goronzy1, Cornelia M Weyand1. 1. Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA. 2. Department of Internal Medicine, Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, Netherlands. 3. Department of Pathology, Stanford University School of Medicine, Stanford, California, USA. 4. Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 5. Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California USA.
Abstract
BACKGROUND: In inflammatory blood vessel diseases, macrophages represent a key component of the vascular infiltrates and are responsible for tissue injury and wall remodeling. METHODS: To examine whether inflammatory macrophages in the vessel wall display a single distinctive effector program, we compared functional profiles in patients with either coronary artery disease (CAD) or giant cell arteritis (GCA). RESULTS: Unexpectedly, monocyte-derived macrophages from the 2 patient cohorts displayed disease-specific signatures and differed fundamentally in metabolic fitness. Macrophages from CAD patients were high producers for T cell chemoattractants (CXCL9, CXCL10), the cytokines IL-1β and IL-6, and the immunoinhibitory ligand PD-L1. In contrast, macrophages from GCA patients upregulated production of T cell chemoattractants (CXCL9, CXCL10) but not IL-1β and IL-6, and were distinctly low for PD-L1 expression. Notably, disease-specific effector profiles were already identifiable in circulating monocytes. The chemokinehicytokinehiPD-L1hi signature in CAD macrophages was sustained by excess uptake and breakdown of glucose, placing metabolic control upstream of inflammatory function. CONCLUSIONS: We conclude that monocytes and macrophages contribute to vascular inflammation in a disease-specific and discernible pattern, have choices to commit to different functional trajectories, are dependent on glucose availability in their immediate microenvironment, and possess memory in their lineage commitment. FUNDING: Supported by the NIH (R01 AR042527, R01 HL117913, R01 AI108906, P01 HL129941, R01 AI108891, R01 AG045779 U19 AI057266, R01 AI129191), I01 BX001669, and the Cahill Discovery Fund.
BACKGROUND: In inflammatory blood vessel diseases, macrophages represent a key component of the vascular infiltrates and are responsible for tissue injury and wall remodeling. METHODS: To examine whether inflammatory macrophages in the vessel wall display a single distinctive effector program, we compared functional profiles in patients with either coronary artery disease (CAD) or giant cell arteritis (GCA). RESULTS: Unexpectedly, monocyte-derived macrophages from the 2 patient cohorts displayed disease-specific signatures and differed fundamentally in metabolic fitness. Macrophages from CAD patients were high producers for T cell chemoattractants (CXCL9, CXCL10), the cytokines IL-1β and IL-6, and the immunoinhibitory ligand PD-L1. In contrast, macrophages from GCA patients upregulated production of T cell chemoattractants (CXCL9, CXCL10) but not IL-1β and IL-6, and were distinctly low for PD-L1 expression. Notably, disease-specific effector profiles were already identifiable in circulating monocytes. The chemokinehicytokinehiPD-L1hi signature in CAD macrophages was sustained by excess uptake and breakdown of glucose, placing metabolic control upstream of inflammatory function. CONCLUSIONS: We conclude that monocytes and macrophages contribute to vascular inflammation in a disease-specific and discernible pattern, have choices to commit to different functional trajectories, are dependent on glucose availability in their immediate microenvironment, and possess memory in their lineage commitment. FUNDING: Supported by the NIH (R01 AR042527, R01 HL117913, R01 AI108906, P01 HL129941, R01 AI108891, R01 AG045779 U19 AI057266, R01 AI129191), I01 BX001669, and the Cahill Discovery Fund.
Authors: Ryu Watanabe; Toshihisa Maeda; Hui Zhang; Gerald J Berry; Markus Zeisbrich; Robert Brockett; Andrew E Greenstein; Lu Tian; Jörg J Goronzy; Cornelia M Weyand Journal: Circ Res Date: 2018-08-31 Impact factor: 17.367
Authors: Frank A W Verreck; Tjitske de Boer; Dennis M L Langenberg; Marieke A Hoeve; Matthijs Kramer; Elena Vaisberg; Robert Kastelein; Arend Kolk; René de Waal-Malefyt; Tom H M Ottenhoff Journal: Proc Natl Acad Sci U S A Date: 2004-03-19 Impact factor: 11.205
Authors: Prabhakara R Nagareddy; Andrew J Murphy; Roslynn A Stirzaker; Yunying Hu; Shiquing Yu; Rachel G Miller; Bhama Ramkhelawon; Emilie Distel; Marit Westerterp; Li-Shin Huang; Ann Marie Schmidt; Trevor J Orchard; Edward A Fisher; Alan R Tall; Ira J Goldberg Journal: Cell Metab Date: 2013-05-07 Impact factor: 27.287
Authors: Karin Jakobsson; Lennart Jacobsson; Kenneth Warrington; Eric L Matteson; Kimberly Liang; Olle Melander; Carl Turesson Journal: Rheumatology (Oxford) Date: 2014-09-05 Impact factor: 7.580
Authors: Markus Zeisbrich; Nina Chevalier; Bettina Sehnert; Marta Rizzi; Nils Venhoff; Jens Thiel; Reinhard E Voll Journal: Front Immunol Date: 2021-05-24 Impact factor: 7.561